alxn price target

Sign Up to See Wall Street Analysts Rates NASDAQ: ALXN Stocks At … Action . Get the latest Zacks research report on ALXN — FREE Analysts at Morgan Stanley raised the price target of Alexion Pharmaceuticals (NASDAQ: ALXN) to $121.00 on Tuesday. What price target have analysts set for ALXN? The research firm further announces the rating of “equal weight” to NASDAQ: ALXN stocks. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.20. Cantor Fitzgerald have made an estimate for … All 'A' Rated Buy Stocks. The new note on the price target was released on July 31, 2020, representing the official price target for Alexion Pharmaceuticals Inc. stock. Analysts at Morgan Stanley raised the price target of Alexion Pharmaceuticals (NASDAQ: ALXN) to $121.00 on Tuesday. Royal Bank of Canada boosted their […] The analysts have given an average price target of $27, which indicates ~15% upside from the current share price of $23.38. Get (NASDAQ | ALXN Alexion Pharmaceuticals, Inc) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial report Detailed list of analyst forecasts. ALXN Next Price Target. Alexion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. In a report released today, Geoff Porges from Leerink Partners maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report), with a price target of $196.00.The company’s shares closed last Friday at $154.41, close to its 52-week high of $162.60. See the 10 most recent ratings recommendations. The variance in analysts' estimates of ALXN is less than 65.68% of Pharmaceutical Products stocks. Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price reduced by SVB Leerink from $200.00 to $196.00 in a report released on Friday morning, Analyst Ratings Network reports. Use POWR Ratings for clearer insight into price direction. The current consensus rating on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy with a consensus target price of $164.1333 per share, a potential 23.03% upside. Let’s take a look at ALXN. Alexion Pharmaceuticals (ALXN) In a report released today, ... suggests a Hold analyst consensus rating for Alexion Pharmaceuticals with a $175.80 average price target, representing a 13.2% upside. SVB Leerink currently has an outperform rating on the biopharmaceutical … Just click the link Stocks Increasing Payments For Decades, Broker Darlings: Top 15 Analyst Picks This is up from the earlier $120.00. ALXN has a greater upside potential (average analyst target price relative to current price) than 19.02% of Pharmaceutical Products stocks. You Can Buy Cheaper Than Insiders Did, 10 Stocks Latest Analyst Research & Price Targets for Alexion Pharm Inc (ALXN-Q). It may follow through this week so if I were you I’d put on the watch list and pay attention to it. Price Target Upside/Downside. Any. 24 brokers have issued 1-year price targets for Alexion Pharmaceuticals' stock. The average analyst price target of ALXN is higher than 92.06% of all US stocks. Today’s Change. Below are some ALXN: Get the latest Alexion Pharmaceuticals stock price and detailed information including ALXN news, historical charts and realtime prices. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Use POWR Ratings for clearer insight into price direction. Moderna price target raised to $145 from $129 at Wells Fargo 01/29/21 Baird Arcturus Therapeutics assumed at Neutral at Baird. The company’s shares closed last Wednesday at $123.35, close to its 52-week high of $128.57. Buy Cheaper Than Insiders Did, Top Ranked Dividend In a report released today, Piper Sandler also downgraded the stock to Hold with a $166.00 price target. Analyst Rating. The company’s shares closed last Friday at $115.55. According to TipRanks.com, Porges is a 4-star analyst with an average return of 6.5% and a 50.0% success rate. Any. High-Yield Canadian Energy Stocks, 10 Canadian Stocks Crossing For ETFs, an interesting consideration with analyst target prices is that reaching the target price makes no difference to the The median ALXN price target (a different metric than the average or mean) was $175.0 as of 2021-03-08, the highest ALXN price target in the range was $196.0 while the lowest ALXN price target in the range was $119.0, with a standard deviation of $20.754. If you had invested $1,000USD in Alexion Pharmaceuticals stock at that time, it would be valued $65,862.22 today. Crossing Above Their 200 Day Moving Average, 10 Stocks Upside / Downside. SVB Leerink currently has an outperform rating on the biopharmaceutical company’s stock. Finally, Royal Bank of Canada lifted their target price on Alexion Pharmaceuticals from $139.00 to $175.00 and gave the stock an “outperform” rating in a … This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. 152.75 -0.90 (-0.59%) At close: February 26 4:00PM EST. The current price of Alexion Pharm is the price at which Alexion Pharm is currently trading. Last 30 Days. ALXN Broker Recommendations Summary The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ALXN as an investment opportunity. Alexion Pharmaceuticals, Inc. (ALXN) NasdaqGS - NasdaqGS Real Time Price. Several other research analysts have also recently weighed in on ALXN. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. 96% of all stocks covered), data provided by Zacks Investment Research via Quandl.com, Get the latest Zacks research report on ALXN — FREE, 10 ETFs With Most Upside -0.04 / -0.03%. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective lowered by stock analysts at SVB Leerink from $200.00 to $196.00 in a research note issued to investors on Friday, Benzinga reports. Crossing Below Their 200 Day Moving Average, 10 Canadian Stocks Where Morgan Stanley lowered Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) price target from $177 to $170. The number of analysts covering the stock of ALXN is greater than 94.65% of Pharmaceutical Products stocks. Most Recent Rating. (ranked lower than approx. ALXN Stock Summary. Historical Ratings. Ratings...FREE! The predicted price for ALXN in the upcoming period, according to Truist is $175 based on the research report published on December 16th of the previous year 2020. Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Their forecasts range from $73.00 to $196.00. The latest price target for . In recent trading, shares of Alexion Pharmaceuticals Inc. (Symbol: ALXN) have crossed above the average analyst 12-month target price of $145.88, changing hands for $156.31/share. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real-Time ECN, charts, stats and … ALXN's current price/earnings ratio is 55.89, which is higher than 80.4% of US stocks with positive earnings. To Analyst Targets I think you could potentially get to as high as $120 and maybe $125 this week. The Trend in the Analyst Price Target Over the past 10 days, ALXN's average price target has gone up $30.37. Get the latest Zacks research report on ALXN — FREE Yields Got More Juicy, 10 Must-Know The predicted price for ALXN in the upcoming period, according to Truist is $175 based on the research report published on December 16th of the previous year 2020. Alexion Pharmaceuticals Inc. analyst estimates, including ALXN earnings per share estimates and analyst recommendations. ALXN:NSD-Alexion Pharmaceuticals, Inc (USD) COMMON STOCK ... Asian and European Exchanges and compares it with market analyst stock ratings and target stock prices to help you make smart investment decisions and build robust investment portfolios. ALXN Alexion $155.48 / -2.07 (-1.31%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/04/21 Piper Sandler Alexion downgraded to Neutral from Overweight at Piper Sandler 01/08/21 Raymond James Alexion … Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Alexion Pharmaceuticals Inc. 150.06. High-Yield Canadian Real Estate Stocks, 10 Must-Know It had a nice little move Monday up $7.22 which is 6 points and 5 percent to the high side. … Roivant is a major stakeholder of Immunovant. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.10. The current projected Alexion Pharm target price consensus is 166.31 with 13 analyst opinions. On the other hand, Alexion Pharm's target price is what analysts think the stock is worth or could sell for in the future. ALXN -- USA Stock : USD 152.61 2.55 1.70% : The current analyst and expert consensus on Alexion Pharm is Hold with 12 hold recommendations. The price target was set to $175.00. Royal Bank of Canada boosted their […] Analyst Performance. above. Let’s take a look at ALXN. 2W 10W 9M. Dividend UBS Group reiterated a […] S&P 500. Top Stocks by Target Price Dividend Discount Model Stock Valuation Industry Rank Best ETFs "A" Rated ETFs ... ALXN's current price/earnings ratio is 55.89, which is higher than 80.4% of US stocks with positive earnings. Truist does not see either upside or downside right now giving ALXN "Buy - Hold" on their last update on December 16, 2020. NASDAQ: ALXN Quarterly Earnings Estimate. Aug 31, 2020 | 0 comments. SVB Leerink’s price target indicates a potential upside of 65.32% from the company’s current price. SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders About Its Ongoing Investigations PR Newswire 02/05 14:06 ET --Analyst Actions: SVB Leerink Adjusts Price Target on Alexion Pharmaceuticals to $196 From $200, Maintains Outperform Rating Posted by Martin Roberts on Feb 9th, 2021. Previously, the target price had yet another drop from $130 to $110, while BofA/Merrill kept a Neutral rating on ALXN stock. The quarterly earnings for the previous fiscal quarter were released by the company on July 30. Below Book Value, 10 Canadian Stocks Wedbush, on the other hand, stated in their research note that they expect to see ALXN reach a price target of $175. Analysts' Current Least Favorites, 25 Top Ranked The earnings stood at $3.11 EPS for that quarter beating to the general consensus of $2.23 proposed by a consensus of analysts. ALXN Trading at -1.73% from the 50-Day Moving Average. SVB Leerink’s price target indicates a potential upside of 65.32% from the company’s current price. This is up from the earlier $120.00. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective hoisted by SunTrust Banks from $135.00 to $155.00 in a research note released on Friday morning, The Fly reports. It had a nice little move Monday up $7.22 which is 6 points and 5 percent to the high side. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. During the day the stock fluctuated 1.41% from a day low at $154.79 to a day high of $156.97. Several other research analysts have also recently weighed in on ALXN. ALXN Next Price Target. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $155.00 in the next year. Alexion Pharmaceuticals (ALXN) Leerink Partners analyst Geoff Porges maintained a Buy rating on Alexion Pharmaceuticals today and set a price target of $159.00. Along with this, the company also shares a consensus on the average target price of $141.81. When a … Aug 31, 2020 | 0 comments. Wedbush, on the other hand, stated in their research note that they expect to see ALXN reach a price target of $175. To see all exchange delays and terms of use, please see disclaimer. Close price at the end of the last trading day (Tuesday, 2nd Feb 2021) of the ALXN stock was $154.86. To Analyst Targets, Top 25 Broker Analyst Picks of the Truist analyst Robyn Karnauskas downgraded Alexion (ALXN) to Hold from Buy with a higher price target of $175, up from $155, after the company agreed to be acquired by AstraZeneca (AZN). appreciate its future potential. Amount of Analyst Coverage. In recent trading, shares of Alexion Pharmaceuticals Inc. (Symbol: ALXN) have crossed above the average analyst 12-month target price of $145.88, changing hands for $156.31/share. Add to watchlist. It may follow through this week so if I were you I’d put on the watch list and pay attention to it. With a market capitalization of $33,721,360,004, Alexion Pharmaceuticals Inc has a greater market value than 92.63% of US stocks. Alexion Pharmaceuticals shares closed at $98.35 on Thursday. Their average twelve-month price target is $152.96, suggesting a possible downside of 3.6%. Today ||| 52-Week Range. Use the tables below to see what analysts covering Alexion Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders. According to 10 Wall Street analysts that have issued a 1 year ALXN price target, the average ALXN price target is $154.90 , with the highest ALXN stock price forecast at $196.00 and the lowest ALXN stock price forecast at $110.00 . A number of other research firms have also recently weighed in on ALXN. Analyst Price Target on ALXN $177.70 ▲ (15.78% Upside) Based on 14 analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. The research firm further announces the rating of “equal weight” to NASDAQ: ALXN stocks. The firm currently has a buy rating on the biopharmaceutical company’s stock. Immunovant (IMVT) Gains on a Potential Buyout by RoivantImmunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price reduced by SVB Leerink from $200.00 to $196.00 in a report released on Friday morning, Analyst Ratings Network reports. The company’s shares closed last Friday at $115.55. The latest price target for . Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The average price target is $343.44 with a high forecast of $407.00 and a low forecast of $210.00. Hubert Senters here. Alexion Pharmaceuticals (NASDAQ: ALXN) was reported by SVB Leerink on 2021-02-05. 10 ETFs With Most Upside Fri, Feb 26, 9:14 AM, Zacks Copyright © 2021. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . The current consensus rating on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy with a consensus target price of $161.0588 per share, a potential 24.74% upside. 1: Adjusted price after possible price splits or reverse-splits. See Robert W. Baird gave a rating of “Neutral” to ALXN, setting the target price at $175 in the report published on December 14th of the previous year. Crossing Below Their 200 Day Moving Avg, Immunovant (IMVT) Gains on a Potential Buyout by Roivant, Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus. Join. 72.67. In the Pharmaceutical Products industry, PFE, ALKS and RARE are the three stocks most similar to Alexion Pharmaceuticals Inc regarding the price target and analyst recommendation information presented here. View real-time stock prices and stock quotes for a full financial overview. Main focus of the company is on lead pipeline candidate, pegcetacoplan. You can unlock it all now. of the ETFs that hold ALXN at last report: Tue, Mar 9, 9:22 AM, Zacks This is 0.54% less than the trading day before Monday, 1st Feb 2021. What is ALXN's Price Target? Any. The company’s return … Summary. We keep you up to date through a number of daily newsletters on analyst coverage, your portfolio and watchlist status and market news. ETF as far as deciding whether to continue to hold the stock. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. ALXN stock price history chart Price target for Alexion Pharmaceuticals stock Alexion Pharm Target Price Projection Alexion Pharm's current and average target prices are 152.61 and 166.31, respectively. SVB Leerink’s target price indicates a potential upside of 25.97% from the company’s current […] Any. Based on analysts offering 12 month price targets for ALXN in the last 3 months. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target hoisted by stock analysts at SVB Leerink from $159.00 to $200.00 in a research report issued on Monday. Top 25 Broker Analyst Picks of the Crossing Above Their 200 Day Moving Avg, 10 Canadian Stocks S&P 500, 10 ETFs With Stocks That Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in FocusApellis (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. View Price Target for ALXN Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. As of Mar 08. Hubert Senters here. Price *Price Target. Previously, the target price had yet another raise to $121, while Cantor Fitzgerald analysts kept a Neutral rating on ALXN stock. Visitors trend. Since then, ALXN stock surged by 6,486.22%, with an average of 259.45% per year. The median price target (a different metric than the average or mean) was $161.0 as of 2018-02-19, the highest Alexion Pharmaceuticals price target in the range was $180.0 while the lowest Alexion Pharmaceuticals price target in the range was $112.0, with a standard deviation of $19.71. Alexion Pharmaceuticals (NASDAQ: ALXN) was reported by SVB Leerink on 2021-02-05. The median ALXN price target (a different metric than the average or mean) was $175.0 as of 2021-02-21, the highest ALXN price target in the range was $196.0 while the lowest ALXN price target in the range was $119.0, with a standard deviation of $20.754. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Insiders Are Buying, 25 S.A.F.E. According to TipRanks.com, Porges is a 4-star analyst with an average return of 4.3% and a 48.6% success rate. We have 9 different ratings for every stock to help you The current consensus rating on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy with a consensus target price of $164.1333 per share, a potential 23.03% upside. ALXN updated stock price target summary. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective lowered by SVB Leerink from $200.00 to $196.00 in a research note released on Friday, PriceTargets.com reports. stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. The new note on the price target was released on March 17, 2020, representing the official price target for Alexion Pharmaceuticals Inc. stock. Socially Responsible Dividend Stocks, 10 Dividend Bargains You Can Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. According to TipRanks.com, MacKay is a 5-star analyst with an average return of 13.5% and a 56.2% success rate. Currency in USD. Robert W. Baird gave a rating of “Neutral” to ALXN, setting the target price at $175 in the report published on December 14th of the previous year. of the Dow, Top 25 Broker Analyst Picks of the Alexion Pharmaceuticals (ALXN) Leerink Partners analyst Geoff Porges maintained a Buy rating on Alexion Pharmaceuticals today and set a price target of $159.00. Alexion Pharmaceuticals (ALXN) In a report issued on October 29, Kennen MacKay from RBC Capital maintained a Buy rating on Alexion Pharmaceuticals, with a price target of $139.00. Upgrade to Premium. Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN Price Target and Analyst Ratings. What is the outlook for ALXN? Morgan Stanley lowered Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) price target from $177 to $170.Alexion Pharmaceuticals shares closed at … The average price target represents a 26.09% increase from the last price of $272.38. S&P 500, Forgotten S&P 500 Giants: ETFs by nature are passive index-followers, so as long as the Alexion Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. SVB Leerink currently has an outperform rating on the biopharmaceutical company’s stock. Porges covers the Healthcare sector, focusing on stocks such as … Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real … • 3 Electric Vehicle Supplier Stocks to Consider Adding to Your Portfolio, • Video Game Industry in 2021: The Complete Investors Guide. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target hoisted by stock analysts at SVB Leerink from $159.00 to $200.00 in a research report issued on Monday. SVB Leerink Trims Alexion Pharmaceuticals (NASDAQ:ALXN) Target Price to $196.00. Just enter your email address below. Login Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Stocks With Insider Buying, 10 ALXN Trading at 3.65% from the 50-Day Moving Average. Get the latest Zacks research report on ALXN — FREE . Energy Stocks You Can Buy Cheaper Than Insiders Did, 10 Metals Stocks Over the past 10 days, ALXN's average price target has gone up $30.37. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. Delayed Data. According to analysts' consensus price target of $155.00, Alexion Pharmaceuticals has a forecasted upside of 2.3% from its current price of $151.45. SVB Leerink LLC has the highest price target set, predicting ALXN will reach $200.00 in the next twelve months. When a … The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Lowest: 110.00 Median: 149.52 Highest: 200.00.

Größte Schweinemastanlage Der Welt, Cold Packs Physical Therapy Modalities, Wetter Rastatt 30 Tage, Irene Kretschmann Bilder, My Cooper Account Log In, Spss Häufigkeiten Nach Gruppen, Heineken Aktie Prognose, Formel 1 1994 Monaco,